FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902027579> ?p ?o ?g. }

• W2902027579 endingPage "4617" @default.
• W2902027579 startingPage "4611" @default.
• W2902027579 abstract "Background: Accurate histopathological evaluation of lymph nodes (LNs) is essential for reliable staging in prostate cancer. In routine practice, conventional techniques only examine parts of the LN. Molecular nodal staging methods are limited by their high costs and extensive time requirement. One-step nucleic acid amplification (OSNA) determines the metastatic status of the complete LN and allows for rapid intraoperative detection of LN metastases. OSNA has been proposed for diagnosis of LN metastases from breast cancer by quantifying the CK19 mRNA copy number. To provide basic data for OSNA development for prostate cancer, we conducted an investigation of CK19 and OSNA in prostate cancer specimens. Methods: OSNA is based on a short homogenization step and subsequent automated amplification of CK19 mRNA directly from the sample lysate, with results available in 30-40 min. A total of 20 prostate cancer specimens from consecutive patients with intermediate or high-risk prostate cancer (Gleason-Score ≥7) were investigated by both OSNA and conventional histopathology (H&E staining, CK19 immunohistochemistry). OSNA was performed on frozen samples using a ready-to-use amplification kit in an automated real-time detection system. Samples were defined as 'negative' or 'positive' according to mRNA copy number: >5000 copies/µl (++), 250-5000 copies/µl (+), and <250 copies/µl (-). Results: Histopathological analysis confirmed prostate cancer in all samples: Gleason score 7 (n=11), Gleason score 8 (n=2), and Gleason score 9 (n=6). Gleason score could not be given for one patient who previously underwent hormonal treatment. OSNA analysis detected CK19 expression in 100% of the specimens and high numbers of CK19 mRNA copies in all cases (9 samples ++; 11 samples +). Immunohistochemistry confirmed CK19 expression in 19 of 20 cases. In the immunohistochemistry CK19-negative patient, a Gleason score 9 prostate cancer was diagnosed. Conclusions: This is the first study using OSNA to detect CK19 expression in prostate cancer. Initial data indicate that this rapid method for molecular LN staging reliably identifies CK19 mRNA in prostate cancer. These results suggest that the OSNA assay may be suitable to improve (intraoperative) LN staging in prostate cancer. For further verification, OSNA analysis of LN specimens from prostate cancer patients is required." @default.
• W2902027579 created "2018-12-11" @default.
• W2902027579 creator A5011811973 @default.
• W2902027579 creator A5016640567 @default.
• W2902027579 creator A5020046376 @default.
• W2902027579 creator A5032969951 @default.
• W2902027579 creator A5050019012 @default.
• W2902027579 creator A5051997392 @default.
• W2902027579 creator A5080370232 @default.
• W2902027579 date "2018-01-01" @default.
• W2902027579 modified "2023-10-02" @default.
• W2902027579 title "Detection of CK19 mRNA Using One-step Nucleic Acid Amplification (OSNA) in Prostate Cancer: Preliminary Results" @default.
• W2902027579 cites W189198258 @default.
• W2902027579 cites W1978590275 @default.
• W2902027579 cites W1995116785 @default.
• W2902027579 cites W2000188288 @default.
• W2902027579 cites W2006065724 @default.
• W2902027579 cites W2016145602 @default.
• W2902027579 cites W2021729718 @default.
• W2902027579 cites W2022797199 @default.
• W2902027579 cites W2029168014 @default.
• W2902027579 cites W2036610808 @default.
• W2902027579 cites W2047127733 @default.
• W2902027579 cites W2048588872 @default.
• W2902027579 cites W2054884958 @default.
• W2902027579 cites W2061102189 @default.
• W2902027579 cites W2076560612 @default.
• W2902027579 cites W2094031125 @default.
• W2902027579 cites W2097746568 @default.
• W2902027579 cites W2105275554 @default.
• W2902027579 cites W2120831575 @default.
• W2902027579 cites W2123161437 @default.
• W2902027579 cites W2129264768 @default.
• W2902027579 cites W2143802196 @default.
• W2902027579 cites W2146221195 @default.
• W2902027579 cites W2166644438 @default.
• W2902027579 cites W2166980531 @default.
• W2902027579 cites W2326657743 @default.
• W2902027579 cites W2406629173 @default.
• W2902027579 cites W2414244717 @default.
• W2902027579 cites W2419091242 @default.
• W2902027579 cites W2512327090 @default.
• W2902027579 cites W2519576613 @default.
• W2902027579 cites W2520131803 @default.
• W2902027579 cites W2560664318 @default.
• W2902027579 cites W2569719993 @default.
• W2902027579 cites W2587384404 @default.
• W2902027579 cites W2754606106 @default.
• W2902027579 cites W56116407 @default.
• W2902027579 doi "https://doi.org/10.7150/jca.26794" @default.
• W2902027579 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6299376" @default.
• W2902027579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30588244" @default.
• W2902027579 hasPublicationYear "2018" @default.
• W2902027579 type Work @default.
• W2902027579 sameAs 2902027579 @default.
• W2902027579 citedByCount "13" @default.
• W2902027579 countsByYear W29020275792020 @default.
• W2902027579 countsByYear W29020275792021 @default.
• W2902027579 countsByYear W29020275792022 @default.
• W2902027579 countsByYear W29020275792023 @default.
• W2902027579 crossrefType "journal-article" @default.
• W2902027579 hasAuthorship W2902027579A5011811973 @default.
• W2902027579 hasAuthorship W2902027579A5016640567 @default.
• W2902027579 hasAuthorship W2902027579A5020046376 @default.
• W2902027579 hasAuthorship W2902027579A5032969951 @default.
• W2902027579 hasAuthorship W2902027579A5050019012 @default.
• W2902027579 hasAuthorship W2902027579A5051997392 @default.
• W2902027579 hasAuthorship W2902027579A5080370232 @default.
• W2902027579 hasBestOaLocation W29020275791 @default.
• W2902027579 hasConcept C121608353 @default.
• W2902027579 hasConcept C126322002 @default.
• W2902027579 hasConcept C142724271 @default.
• W2902027579 hasConcept C143998085 @default.
• W2902027579 hasConcept C2776235491 @default.
• W2902027579 hasConcept C2780192828 @default.
• W2902027579 hasConcept C530470458 @default.
• W2902027579 hasConcept C544855455 @default.
• W2902027579 hasConcept C71924100 @default.
• W2902027579 hasConcept C87874733 @default.
• W2902027579 hasConceptScore W2902027579C121608353 @default.
• W2902027579 hasConceptScore W2902027579C126322002 @default.
• W2902027579 hasConceptScore W2902027579C142724271 @default.
• W2902027579 hasConceptScore W2902027579C143998085 @default.
• W2902027579 hasConceptScore W2902027579C2776235491 @default.
• W2902027579 hasConceptScore W2902027579C2780192828 @default.
• W2902027579 hasConceptScore W2902027579C530470458 @default.
• W2902027579 hasConceptScore W2902027579C544855455 @default.
• W2902027579 hasConceptScore W2902027579C71924100 @default.
• W2902027579 hasConceptScore W2902027579C87874733 @default.
• W2902027579 hasIssue "24" @default.
• W2902027579 hasLocation W29020275791 @default.
• W2902027579 hasLocation W29020275792 @default.
• W2902027579 hasLocation W29020275793 @default.
• W2902027579 hasLocation W29020275794 @default.
• W2902027579 hasLocation W29020275795 @default.
• W2902027579 hasOpenAccess W2902027579 @default.
• W2902027579 hasPrimaryLocation W29020275791 @default.
• W2902027579 hasRelatedWork W1980245127 @default.

• next